Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Inclusion Criteria: * Male or female participant aged ≥ 18 years old * Participants with cytologically confirmed and documented treatment naïve, de novo or secondary AML defined by WHO 2016 classification (Arber, 2016). Secondary AML includes: * Previous myelodysplastic syndrome transformed * AML due to exposure to potentially leukemogenic therapies or agents (e.g. radiation therapy, alkylating agents, topoisomerase II inhibitors) with the primary malignancy in remission for at least 3 years * Participants not eligible for standard induction chemotherapy * Aged ≥ 75 years old * Or Age ≥18 years with at least one of the following comorbidities: * Clinically significant heart or lung comorbidities, as reflected by at least one of: * Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected * Forced expiratory volume in 1 second (FEV1) ≤65% of expected * Other contraindication(s) to anthracycline therapy (must be documented) * Other comorbidity that the Investigator judges as incompatible with intensive remission induction chemotherapy, which must be documented * ECOG (Eastern Cooperative Oncology Group) performance status should be (criterion should be rechecked at inclusion visit) ECOG ≤ 2. * Written informed consent obtained prior any study-specific procedure as described in section 13.3 of the protocol. * Adequate renal and hepatic function * Circulating White Blood Cell Count (WBC count) \< 25\*109 G/L (with or without use of h…